Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Let’s start with the cheapest, the yearly FIT, or fecal immunochemical test, which looks for fecal blood that might be caused ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

There's a new blood test to screen for colorectal cancer, but a new study found it's not as effective as a colonoscopy or ...

Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A and ...

Modeling data show Cologuard PlusTM test delivers highest life-years gained with fewest number of colonoscopies among noninvasive colorectal cancer (CRC) screening strategies “Exact Sciences is ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

The FDA has approved the Cologuard Plus test for colorectal cancer screening in adults aged 45 years at average risk for colorectal cancer. The Food and Drug Administration (FDA) has approved the ...

But the new, just-launched version of its Cologuard test could spur top-line growth. The improved cancer diagnostic could also help Exact Sciences reach profitability. An updated version of Exact ...